The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC

Journal of Thoracic Oncology

Volumn 12, Issue 2, 2017, Pages 194-207

  Manegold, Christian ^a   Dingemans, Anne Marie C ^b   Gray, Jhanelle E ^c   Nakagawa, Kazuhiko ^d   Nicolson, Marianne ^e   Peters, Solange ^f   Reck, Martin ^g   Wu, Yi Long ^h   Brustugun, Odd Terje ⁱ   Crinò, Lucio ^j   Felip, Enriqueta ^k   Fennell, Dean ^l   Garrido, Pilar ^m   Huber, Rudolf M ⁿ   Marabelle, Aurélien ^o   Moniuszko, Marcin ^p   Mornex, Françoise ^q   Novello, Silvia ^r   Papotti, Mauro ^r   Pérol, Maurice ^s   Smit, Egbert F ^t   Syrigos, Kostas ^u   van Meerbeeck, Jan P ^v   van Zandwijk, Nico ^w   Chih Hsin Yang, James ^x   Zhou, Caicun ^y   Vokes, Everett ^z   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g Mitglied im DZL   (Germany)

^h GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

^j UNIVERSITY OF PERUGIA   (Italy)

^k VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^l UNIVERSITY OF LEICESTER   (United Kingdom)

^m HOSPITAL RAMÓN Y CAJAL   (Spain)

ⁿ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^o INSTITUT GUSTAVE ROUSSY   (France)

^p MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^q UNIVERSITÉ LYON 1   (France)

^r UNIVERSITY OF TURIN   (Italy)

^s CENTRE LÉON BÉRARD   (France)

^t VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^u UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^v ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^w UNIVERSITY OF SYDNEY   (Australia)

^x NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^y SHANGHAI PULMONARY HOSPITAL   (China)

^z UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

more..

Author keywords

Antiangiogenesis; Combination therapy; Immunotherapy; NSCLC

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; BEVACIZUMAB; CABOZANTINIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DURVALUMAB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; METRONIDAZOLE; NINTEDANIB; NIVOLUMAB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMBROLIZUMAB; PEMETREXED; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; RAMUCIRUMAB; SUNITINIB; ANGIOGENESIS INHIBITOR;

ANTIANGIOGENIC THERAPY; BLEEDING; CANCER IMMUNOTHERAPY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOTOXICITY; MAINTENANCE THERAPY; MONOTHERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; PATHOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS;

EID: 85015304170     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.10.003     Document Type: Review

References (63)

1. 1 Besse, B., Adjei, A., Baas, P., et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol 25 (2014), 1475–1484.
2. 2 National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-small cell lung cancer. Version 4. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed March 21, 2016.
3. 3 Reck, M., Popat, S., Reinmuth, N., De Ruysscher, D., Kerr, K.M., Peters, S., Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25 Suppl 3 (2014), iii27–iii39.
4. 4 Gridelli, C., Ardizzoni, A., Ciardiello, F., et al. Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol 3 (2008), 430–440.
5. 5 Gridelli, C., Rossi, A., Maione, P., et al. The role of maintenance treatment in advanced non-small-cell lung cancer: reality or early second line?. Clin Lung Cancer 11 (2010), 374–382.
6. 6 Stinchcombe, T.E., Socinski, M.A., Considerations for second-line therapy of non-small cell lung cancer. Oncologist 13:suppl 1 (2008), 28–36.
7. 7 Bustamante Alvarez, J.G., Gonzalez-Cao, M., Karachaliou, N., et al. Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med 12 (2015), 209–222.
8. 8 Hall, R.D., Le, T.M., Haggstrom, D.E., Gentzler, R.D., Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 4 (2015), 515–523.
9. 9 Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
10. 10 Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
11. 11 Garon, E.B., Ciuleanu, T.E., Arrieta, O., et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384 (2014), 665–673.
12. 12 Herbst, R.S., Baas, P., Kim, D.W., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
13. 13 Reck, M., Kaiser, R., Mellemgaard, A., et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15 (2014), 143–155.
14. 14 Ott, P.A., Hodi, F.S., Buchbinder, E.I., Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front Oncol, 5, 2015, 202.
15. 15 Ferrara, N., VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 20 (2009), 158–163.
16. 16 Nagy, J.A., Dvorak, A.M., Dvorak, H.F., VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2 (2007), 251–275.
17. 17 Carmeliet, P., Jain, R.K., Molecular mechanisms and clinical applications of angiogenesis. Nature 473 (2011), 298–307.
18. 18 Ramalingam, S.S., Shtivelband, M., Soo, R.A., et al. Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 33 (2015), 433–441.
19. 19 Folkman, J., Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971), 1182–1186.
20. 20 Soria, J.C., Mauguen, A., Reck, M., et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 24 (2013), 20–30.
21. 21 Herbst, R.S., Sun, Y., Eberhardt, W.E., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11 (2010), 619–626.
22. 22 Laurie, S.A., Solomon, B.J., Seymour, L., et al. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. Eur J Cancer 50 (2014), 706–712.
23. 23 Paz-Ares, L.G., Biesma, B., Heigener, D., et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 30 (2012), 3084–3092.
24. 24 Scagliotti, G.V., Krzakowski, M., Szczesna, A., et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 30 (2012), 2070–2078.
25. 25 Scagliotti, G.V., Vynnychenko, I., Park, K., et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 30 (2012), 2829–2836.
26. 26 Hilberg, F., Roth, G.J., Krssak, M., et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68 (2008), 4774–4782.
27. 27 Hanna, N.H., Kaiser, R., Sullivan, R.N., et al. Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. [abstract] J Clin Oncol, 31(suppl 15), 2013, 8034.
28. 28 Sandler, A., Gray, R., Perry, M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006), 2542–2550.
29. 29 Zhou, C., Wu, Y.L., Chen, G., et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol 33 (2015), 2197–2204.
30. 30 Reck, M., von Pawel, J., Zatloukal, P., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21 (2010), 1804–1809.
31. 31 Motzer, R.J., Escudier, B., McDermott, D.F., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
32. 32 Robert, C., Long, G.V., Brady, B., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2015), 320–330.
33. 33 Schadendorf, D., Hodi, F.S., Robert, C., et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33 (2015), 1889–1894.
34. 34 Roche. U.S. FDA grants breakthrough therapy designation for Roche's investigational immunotherapy MPDL3280L (antiPDL-1) in non-small cell lung cancer. Second FDA breakthrough therapy designation for MPDL3280L following bladder cancer in 2014. http://www.roche.com/media/store/releases/med-cor-2015-02-02.htm. Accessed March 21, 2016.
35. 35 Fehrenbacher, L., Spira, A., Ballinger, M., et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (2016), 1837–1846.
36. 36 Bouzin, C., Brouet, A., De Vriese, J., Dewever, J., Feron, O., Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol 178 (2007), 1505–1511.
37. 37 Finke, J.H., Rini, B., Ireland, J., et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 14 (2008), 6674–6682.
38. 38 Gabrilovich, D., Ishida, T., Oyama, T., et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92 (1998), 4150–4166.
39. 39 Gabrilovich, D.I., Chen, H.L., Girgis, K.R., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2 (1996), 1096–1103.
40. 40 Motz, G.T., Santoro, S.P., Wang, L.P., et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 20 (2014), 607–615.
41. 41 Ohm, J.E., Carbone, D.P., VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 23 (2001), 263–272.
42. 42 Ohm, J.E., Gabrilovich, D.I., Sempowski, G.D., et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101 (2003), 4878–4886.
43. 43 Terme, M., Pernot, S., Marcheteau, E., et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 73 (2013), 539–549.
44. 44 Garber, K., Promising early results for immunotherapy-antiangiogenesis combination. J Natl Cancer Inst, 106, 2014 pii: dju392.
45. 45 Metpally, R.P.R., Nasser, S., Malenica, I., et al. Comparison of analysis tools for miRNA high throughput sequencing using nerve crush as a model. Front Genet, 4, 2013, 20.
46. 46 Kwilas, A.R., Ardiani, A., Donahue, R.N., Aftab, D.T., Hodge, J.W., Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med, 12, 2014, 294.
47. 47 Li, B., Lalani, A.S., Harding, T.C., et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 12 (2006), 6808–6816.
48. 48 Shi, S., Wang, R., Chen, Y., Song, H., Chen, L., Huang, G., Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models. PLoS One, 8, 2013, e65757.
49. 49 Tao, L., Huang, G., Shi, S., Chen, L., Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models. Med Oncol, 31, 2014, 777.
50. 50 Yasuda, S., Sho, M., Yamato, I., et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin Exp Immunol 172 (2013), 500–506.
51. 51 Ko, J.S., Zea, A.H., Rini, B.I., et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15 (2009), 2148–2157.
52. 52 Voron, T., Colussi, O., Marcheteau, E., et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 212 (2015), 139–148.
53. 53 Farsaci, B., Donahue, R.N., Coplin, M.A., et al. Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. Cancer Immunol Res 2 (2014), 1090–1102.
54. 54 Farsaci, B., Higgins, J.P., Hodge, J.W., Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer 130 (2012), 1948–1959.
55. 55 Huang, Y., Yuan, J., Righi, E., et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 109 (2012), 17561–17566.
56. 56 Herbst, R.S., Bendell, J.C., Isambert, N., et al. A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, nonsmall cell lung cancer (NSCLC), or urothelial carcinoma (UC): phase 1a results. [abstract] J Clin Oncol, 34(suppl), 2016, 3056.
57. 57 Rizvi, N.A., Antonia, S.J., Shepherd, F.A., et al. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) maintenance as monotherapy or in combination with bevacizumab (BEV) for non-small cell lung cancer (NSCLC) previously treated with chemotherapy. Radiation Oncol, 90(suppl 5), 2014, S32.
58. 58 Bendell, J.C., Powderly, J.D., Lieu, C.H., et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). [abstract] J Clin Oncol, 33(suppl 3), 2015, 704.
59. 59 Amin, A., Plimack, E.R., Infante, J.R., et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma(mRCC). [abstract] J Clin Oncol, 32(suppl), 2014, 5010.
60. 60 Dudek, A.Z., Sica, R.A., Sidani, A., et al. Phase Ib study of pembrolizumab in combination with bevacizumab for the treatment of metastatic renal cell carcinoma: Big Ten Cancer Research Consortium BTCRCGU14003. [abstract] J Clin Oncol, 34(suppl 2S), 2016, 559.
61. 61 Sznol, M., McDermott, D.F., Fields Jones, S., et al. Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC). [abstract] J Clin Oncol, 33(suppl 7), 2015, 410.
62. 62 Hodi, F.S., Lawrence, D., Lezcano, C., et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2 (2014), 632–642.
63. 63 Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.